Jeremy Barbera is a media and technology entrepreneur specializing in the development and implementation of disruptive innovative technologies. He has co-developed with NASA a nanotechnology breath analysis sensor that attaches to a smart phone that will be used in the field mobile health screening.
Mr. Barbera is the Chairman of the Board and Chief Executive Officer of Vantage Health Inc. since November 8th 2013. He has been an entrepreneur since leaving his position as NASA. He was a research scientist based at NASA/Goddard Space Flight Center and NASA/Goddard Institute for Space Studies, working on such groundbreaking missions as Pioneer Venus and the Global Atmospheric Research Program. Mr. Barbera is a Physicist educated at New York University and Massachusetts Institute of Technology.
Vantage Health Inc. - a leader in mobile health technology - is developing personalized and point-of-care screening using Apps based upon chemical sensing on a small device attached to a smartphone.
With its foundations in advanced nanotechnology, the company’s first product, the Vantage Sensor, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application.
The first mobile App is expected to be for lung cancer screening with additional mobile healthcare apps in the planning stages. The company has offices in Redwood City, CA and New York. For more information, please visit http://www.vantagehealthinc.com
Vantage Health in the News
USA TODAY - The Future Of Health Care Is Social And Techie
March 8, 2014
ISSUU - Government Health Care United States Buyers Guide: Winter 2014
Meditek - Could A Smartphone Detect Lung Cancer?
Mobile Health News - Scripps To Test NASA-Developed, Smartphone-Enabled Lung Cancer Sensor
February 11, 2014
Independant Valuations of VNTH
WealthMakers target of $ .50 and a short squeeze valuation of $2.85
WEALTHMAKERS.COM Issues Report on Vantage Health
Wed Feb 26, 7:23AM CST
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a new research report today on Vantage Health, Inc. (OTC: VNTH). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $0.095 and the projected short squeeze price target of $2.85 per share.
BUYINS.NET Issues Vantage Health SqueezeTrigger Report
Thu Feb 13, 7:27AM CST
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Vantage Health (OTCBB: VNTH) after releasing the latest short sale data through February 11, 2014. The total aggregate number of shares shorted since March 2011 is approximately 23.35 million shares. Approximately 21.83% of daily trading volume is short selling.